“Wendy Young”的意思、由来-开放百科全书

Wendy B. Young is a medicinal chemist and pharmaceutical executive currently employed at Genentech.

Education

Young received her B.S. and M.S. from Wake Forest University, working with Prof. Huw Davies.^[1] She was co-author on an early application of Davies' rhodium(II) carbenoid insertion - Cope rearrangement chemistry, leading to the total synthesis of three small tropane natural products.^[2] Young received her Ph.D. from Princeton in 1993, working with Edward C. Taylor on heterocycles^[3] derived from natural pigments, one of which ultimately became pemetrexed^[4] (Alimta)^[5], an oncology treatment. In her postdoctoral fellowship with Samuel Danishefsky, Young was among one of a handful of groups in the mid-1990s to synthesize paclitaxel (Taxol),^[6] a highly-oxegenated terpenoid natural product used to treat cancer.

Career

Despite multiple employment offers on the East Coast of the United States,^[1] Young chose to remain in the San Francisco Bay Area for her professional career. From 1995 to 2006, Young worked at Celera Genomics, studying inhibitor compounds of human plasma proteins^[7] such as kallikrein and Factors VIIa and IXa. She was recruited to Genentech in 2006, and in 2018 was promoted to Senior Vice President of Small Molecule drug discovery.^[1] One of her major research successes was development of a chemistry campaign against Bruton's tyrosine kinase, leading to molecules to potentially treat rheumatoid arthritis and B-cell lymphomas.^[8] Her team developed fenebrutinib, currently in Phase II trials for several autoimmune disorders.^[9]

Awards

References

1. ^¹²{{Cite news|url=https://www.gene.com/stories/the-molecule-maker|title=The Molecule Maker|last=Genentech|work=Genentech: Breakthrough science. One moment, one day, one person at a time.|access-date=2018-10-27}}
2. ^{{Cite journal|last=Davies|first=Huw M. L.|last2=Saikali|first2=Elie|last3=Young|first3=Wendy B.|date=1991|title=Synthesis of (.+-.)-ferruginine and (.+-.)-anhydroecgonine methyl-ester by a tandem cyclopropanation/Cope rearrangement|journal=The Journal of Organic Chemistry|language=EN|volume=56|issue=19|pages=5696–5700|doi=10.1021/jo00019a044|issn=0022-3263}}
3. ^{{Cite web|url=https://www.heterocycles.jp/newlibrary/libraries/abst/05123|title=HeteroCycles|website=www.heterocycles.jp|language=en|access-date=2018-10-27}}
4. ^{{Cite news|url=https://www.princeton.edu/news/2017/11/29/princeton-chemist-edward-c-taylor-inventor-anti-cancer-drug-dies-94|title=Princeton chemist Edward C. Taylor, inventor of anti-cancer drug, dies at 94|work=Princeton University|access-date=2018-10-27|language=en}}
5. ^{{Cite news|url=https://www.drugs.com/monograph/alimta.html|title=Alimta Monograph for Professionals - Drugs.com|work=Drugs.com|access-date=2018-10-27|language=en-US}}
6. ^{{Cite journal|last=Masters|first=John J.|last2=Link|first2=J. T.|last3=Snyder|first3=Lawrence B.|last4=Young|first4=Wendy B.|last5=Danishefsky|first5=Samuel J.|date=1995-09-01|title=A Total Synthesis of Taxol|journal=Angewandte Chemie International Edition in English|language=en|volume=34|issue=16|pages=1723–1726|doi=10.1002/anie.199517231|issn=0570-0833}}
7. ^{{Cite journal|last=Tang|first=Jie|last2=Yu|first2=Christine Luong|last3=Williams|first3=Steven R.|last4=Springman|first4=Eric|last5=Jeffery|first5=Douglas|last6=Sprengeler|first6=Paul A.|last7=Estevez|first7=Alberto|last8=Sampang|first8=Jun|last9=Shrader|first9=William|date=2005-12-09|title=Expression, Crystallization, and Three-dimensional Structure of the Catalytic Domain of Human Plasma Kallikrein|url=http://www.jbc.org/content/280/49/41077|journal=Journal of Biological Chemistry|language=en|volume=280|issue=49|pages=41077–41089|doi=10.1074/jbc.M506766200|issn=0021-9258|pmid=16199530}}
8. ^{{Cite journal|last=Wang|first=Xiaojing|last2=Barbosa|first2=James|last3=Blomgren|first3=Peter|last4=Bremer|first4=Meire C.|last5=Chen|first5=Jacob|last6=Crawford|first6=James J.|last7=Deng|first7=Wei|last8=Dong|first8=Liming|last9=Eigenbrot|first9=Charles|date=2017-05-03|title=Discovery of Potent and Selective Tricyclic Inhibitors of Bruton's Tyrosine Kinase with Improved Druglike Properties |url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5467183/|journal=ACS Medicinal Chemistry Letters|volume=8|issue=6|pages=608–613|doi=10.1021/acsmedchemlett.7b00103|issn=1948-5875|pmc=5467183|pmid=28626519}}
9. ^{{Cite news|url=https://clinicaltrials.gov/ct2/show/NCT03693625|title=A Study to Evaluate the Long-term Safety and Efficacy of Fenebrutinib in Participants Previously Enrolled in a Fenebrutinib Chronic Spontaneous Urticaria (CSU) Study - Full Text View - ClinicalTrials.gov|access-date=2018-10-27|language=en}}
10. ^{{Cite web|url=https://johnsonsymposium.stanford.edu/wendy-young-genentech|title=Wendy Young, Genentech {{!}} William S. Johnson Symposium|website=johnsonsymposium.stanford.edu|language=en|access-date=2018-10-27}}
11. ^{{Cite web|url=https://www.gene.com/scientists/our-scientists/wendy-young|title=Genentech: Wendy Young {{!}} Senior Vice President, Small Molecule Drug Discovery|website=www.gene.com|access-date=2018-10-27}}
12. ^{{Cite web|url=https://www.acsmedchem.org/?nd=ecmembers|title=Executive Committee|last=2018|first=2014,|website=www.acsmedchem.org|access-date=2018-10-27}}